Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,666
archived clinical trials in
Hospital

A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated:  11/2/2015
St. Peter's Hospital
mi
from
Albany, NY
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated: 11/2/2015
St. Peter's Hospital
mi
from
Albany, NY
Click here to add this to my saved trials
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated:  11/2/2015
Columbia University
mi
from
New York, NY
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated: 11/2/2015
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated:  11/2/2015
Duke Univ Med Ctr
mi
from
Durham, NC
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated: 11/2/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated:  11/2/2015
Durham VA Medical Center
mi
from
Durham, NC
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated: 11/2/2015
Durham VA Medical Center
mi
from
Durham, NC
Click here to add this to my saved trials
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated:  11/2/2015
The Lindner Research Center, The Christ Hospital
mi
from
Cincinnati, OH
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated: 11/2/2015
The Lindner Research Center, The Christ Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated:  11/2/2015
Erlanger Health System
mi
from
Chattanooga, TN
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated: 11/2/2015
Erlanger Health System
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated:  11/2/2015
Memorial Hospital
mi
from
Chattanooga, TN
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated: 11/2/2015
Memorial Hospital
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated:  11/2/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated: 11/2/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated:  11/2/2015
Baylor University Medical Center, Soltero Cardiovascular Research Center
mi
from
Dallas, TX
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated: 11/2/2015
Baylor University Medical Center, Soltero Cardiovascular Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated:  11/2/2015
Cardiothoracic Surgical Associates
mi
from
Richmond, VA
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated: 11/2/2015
Cardiothoracic Surgical Associates
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated:  11/2/2015
Ohio State University Medical Center
mi
from
Columbus, OH
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated: 11/2/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated:  11/2/2015
The University of Texas, Houston
mi
from
Houston, TX
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated: 11/2/2015
The University of Texas, Houston
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated:  11/2/2015
Foothills Medical Centre
mi
from
Calgary,
A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Status: Enrolling
Updated: 11/2/2015
Foothills Medical Centre
mi
from
Calgary,
Click here to add this to my saved trials
How Your Patients' Non-REM Sleep Changes On Sedatives in the Intensive Care Units
Comparison of Polysomnographic Findings in Mechanically Ventilated Patients Sedated With α2 Agonists Versus GABA Agonists
Status: Enrolling
Updated:  11/4/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
How Your Patients' Non-REM Sleep Changes On Sedatives in the Intensive Care Units
Comparison of Polysomnographic Findings in Mechanically Ventilated Patients Sedated With α2 Agonists Versus GABA Agonists
Status: Enrolling
Updated: 11/4/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Sub-Acute Pulmonary Dysfunction Following Allogeneic Stem Cell Transplantation. A Phase II Study
Status: Enrolling
Updated:  11/4/2015
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Sub-Acute Pulmonary Dysfunction Following Allogeneic Stem Cell Transplantation. A Phase II Study
Status: Enrolling
Updated: 11/4/2015
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Characteristics of Cord Blood Immunologic Parameters of Infants <32 Weeks Gestation
Characteristics of Cord Blood Immunologic Parameters of Infants < 32 Weeks Gestation
Status: Enrolling
Updated:  11/5/2015
Children's Memorial Hermann Hospital
mi
from
Houston, TX
Characteristics of Cord Blood Immunologic Parameters of Infants <32 Weeks Gestation
Characteristics of Cord Blood Immunologic Parameters of Infants < 32 Weeks Gestation
Status: Enrolling
Updated: 11/5/2015
Children's Memorial Hermann Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Ketamine Versus Etomidate for Rapid Sequence Intubation
Ketamine Versus Etomidate for Sedation of Emergency Department Patients During Rapid Sequence Intubation
Status: Enrolling
Updated:  11/6/2015
Hennepin County Medical Center
mi
from
Minneapolis, MN
Ketamine Versus Etomidate for Rapid Sequence Intubation
Ketamine Versus Etomidate for Sedation of Emergency Department Patients During Rapid Sequence Intubation
Status: Enrolling
Updated: 11/6/2015
Hennepin County Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
STAT-ED: Suicidal Teens Accessing Treatment After an Emergency Department Visit
STAT-ED: Suicidal Teens Accessing Treatment After an Emergency Department Visit
Status: Enrolling
Updated:  11/10/2015
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
STAT-ED: Suicidal Teens Accessing Treatment After an Emergency Department Visit
STAT-ED: Suicidal Teens Accessing Treatment After an Emergency Department Visit
Status: Enrolling
Updated: 11/10/2015
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
STAT-ED: Suicidal Teens Accessing Treatment After an Emergency Department Visit
STAT-ED: Suicidal Teens Accessing Treatment After an Emergency Department Visit
Status: Enrolling
Updated:  11/10/2015
Nationwide Children's Hospital
mi
from
Columbus, OH
STAT-ED: Suicidal Teens Accessing Treatment After an Emergency Department Visit
STAT-ED: Suicidal Teens Accessing Treatment After an Emergency Department Visit
Status: Enrolling
Updated: 11/10/2015
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Estimation of Intrinsic Positive End-Expiratory Pressure (PEEP) in Acute Respiratory Distress Syndrome (ARDS)
Estimation of Intrinsic Positive End-Expiratory Pressure (PEEP) in Acute Respiratory Distress Syndrome (ARDS)
Status: Enrolling
Updated:  11/10/2015
Thomason Hospital (Now University Medical Center)
mi
from
El Paso, TX
Estimation of Intrinsic Positive End-Expiratory Pressure (PEEP) in Acute Respiratory Distress Syndrome (ARDS)
Estimation of Intrinsic Positive End-Expiratory Pressure (PEEP) in Acute Respiratory Distress Syndrome (ARDS)
Status: Enrolling
Updated: 11/10/2015
Thomason Hospital (Now University Medical Center)
mi
from
El Paso, TX
Click here to add this to my saved trials
Evaluation of Myocardial Effects of Bendavia for Reducing Reperfusion Injury in Patients With Acute Coronary Events
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Bendavia (MTP-131) on Reperfusion Injury in Patients Treated With Standard Therapy Including Primary PCI and Stenting for ST-segment Elevation Myocardial Infarction
Status: Enrolling
Updated:  11/11/2015
Advanced Medical Research Center
mi
from
Port Orange, FL
Evaluation of Myocardial Effects of Bendavia for Reducing Reperfusion Injury in Patients With Acute Coronary Events
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Bendavia (MTP-131) on Reperfusion Injury in Patients Treated With Standard Therapy Including Primary PCI and Stenting for ST-segment Elevation Myocardial Infarction
Status: Enrolling
Updated: 11/11/2015
Advanced Medical Research Center
mi
from
Port Orange, FL
Click here to add this to my saved trials
Evaluation of Myocardial Effects of Bendavia for Reducing Reperfusion Injury in Patients With Acute Coronary Events
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Bendavia (MTP-131) on Reperfusion Injury in Patients Treated With Standard Therapy Including Primary PCI and Stenting for ST-segment Elevation Myocardial Infarction
Status: Enrolling
Updated:  11/11/2015
Henry Ford Hospital
mi
from
Detroit, MI
Evaluation of Myocardial Effects of Bendavia for Reducing Reperfusion Injury in Patients With Acute Coronary Events
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Bendavia (MTP-131) on Reperfusion Injury in Patients Treated With Standard Therapy Including Primary PCI and Stenting for ST-segment Elevation Myocardial Infarction
Status: Enrolling
Updated: 11/11/2015
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Evaluation of Myocardial Effects of Bendavia for Reducing Reperfusion Injury in Patients With Acute Coronary Events
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Bendavia (MTP-131) on Reperfusion Injury in Patients Treated With Standard Therapy Including Primary PCI and Stenting for ST-segment Elevation Myocardial Infarction
Status: Enrolling
Updated:  11/11/2015
Creighton Cardiac Center
mi
from
Omaha, NE
Evaluation of Myocardial Effects of Bendavia for Reducing Reperfusion Injury in Patients With Acute Coronary Events
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Bendavia (MTP-131) on Reperfusion Injury in Patients Treated With Standard Therapy Including Primary PCI and Stenting for ST-segment Elevation Myocardial Infarction
Status: Enrolling
Updated: 11/11/2015
Creighton Cardiac Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Evaluation of Myocardial Effects of Bendavia for Reducing Reperfusion Injury in Patients With Acute Coronary Events
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Bendavia (MTP-131) on Reperfusion Injury in Patients Treated With Standard Therapy Including Primary PCI and Stenting for ST-segment Elevation Myocardial Infarction
Status: Enrolling
Updated:  11/11/2015
Universitätsmedizin Berlin, Charité Campus Benjamin Franklin
mi
from
Berlin,
Evaluation of Myocardial Effects of Bendavia for Reducing Reperfusion Injury in Patients With Acute Coronary Events
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Bendavia (MTP-131) on Reperfusion Injury in Patients Treated With Standard Therapy Including Primary PCI and Stenting for ST-segment Elevation Myocardial Infarction
Status: Enrolling
Updated: 11/11/2015
Universitätsmedizin Berlin, Charité Campus Benjamin Franklin
mi
from
Berlin,
Click here to add this to my saved trials
Assessing Eye Tracking Features Following Sports-Related Concussion
Assessing Eye Tracking Features Following Sports-Related Concussion
Status: Enrolling
Updated:  11/11/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Assessing Eye Tracking Features Following Sports-Related Concussion
Assessing Eye Tracking Features Following Sports-Related Concussion
Status: Enrolling
Updated: 11/11/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
UCLA Medical Center
mi
from
Los Angeles, CA
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Stanford Univ Med Ctr
mi
from
Stanford, CA
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
University of Colorado
mi
from
Denver, CO
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
University of Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Yale University
mi
from
New Haven, CT
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
University of Florida
mi
from
Gainsville, FL
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
University of Florida
mi
from
Gainsville, FL
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Tampa General Hospital
mi
from
Tampa, FL
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
University of Chicago
mi
from
Chicago, IL
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
University of Michigan
mi
from
Ann Arbor, MI
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Henry Ford Health Care System
mi
from
Detroit, MI
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Henry Ford Health Care System
mi
from
Detroit, MI
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Columbia University
mi
from
New York, NY
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Nationwide Children's Hospital
mi
from
Columbus, OH
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Albert Einstein Medical Center
mi
from
Philadelphia, PA
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Albert Einstein Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Medical University of South Carolina
mi
from
Charleston, SC
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Methodist Healthcare System
mi
from
San Antonio, TX
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Methodist Healthcare System
mi
from
San Antonio, TX
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
University of Utah
mi
from
Salt Lake City, UT
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Univ of Washington
mi
from
Seattle, WA
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Emory University
mi
from
Atlanta, GA
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Northwestern University Medical Center
mi
from
Chicago, IL
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Northwestern University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Johns Hopkins Hospital
mi
from
Baltimore, MD
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
University of Massachusetts
mi
from
Worcester, MA
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
University of Massachusetts
mi
from
Worcester, MA
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials